DeepLCRmiRNA: A Hybrid Neural Network Approach for Identifying Lung Cancer-Associated miRNAs.

IF 3.8 4区医学 Q2 GENETICS & HEREDITY

Current gene therapy Pub Date : 2024-09-13 DOI:10.2174/0115665232312364240902060458

Nitao Cheng, Chen Chen, Junliang Liu, Xuanchun Wang, Ziqi Gao, Ming Mao, Jingyu Huang

{"title":"DeepLCRmiRNA: A Hybrid Neural Network Approach for Identifying Lung Cancer-Associated miRNAs.","authors":"Nitao Cheng, Chen Chen, Junliang Liu, Xuanchun Wang, Ziqi Gao, Ming Mao, Jingyu Huang","doi":"10.2174/0115665232312364240902060458","DOIUrl":null,"url":null,"abstract":"Introduction: Lung cancer stands as one of the most prevalent malignant neoplasms, with microRNAs (miRNAs) playing a pivotal role in the modulation of gene expression, impacting cancer cell proliferation, invasion, metastasis, immune escape, and resistance to therapy.Method: The intricate role of miRNAs in lung cancer underscores their significance as biomarkers for early detection and as novel targets for therapeutic intervention. Traditional approaches for the identification of miRNAs related to lung cancer, however, are impeded by inefficiencies and complexities.Results: In response to these challenges, this study introduced an innovative deep-learning strategy designed for the efficient and precise identification of lung cancer-associated miRNAs. Through comprehensive benchmark tests, our method exhibited superior performance relative to existing technologies.Conclusion: Further case studies have also confirmed the ability of our model to identify lung cancer-associated miRNAs that have undergone biological validation.","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232312364240902060458","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Lung cancer stands as one of the most prevalent malignant neoplasms, with microRNAs (miRNAs) playing a pivotal role in the modulation of gene expression, impacting cancer cell proliferation, invasion, metastasis, immune escape, and resistance to therapy.

Method: The intricate role of miRNAs in lung cancer underscores their significance as biomarkers for early detection and as novel targets for therapeutic intervention. Traditional approaches for the identification of miRNAs related to lung cancer, however, are impeded by inefficiencies and complexities.

Results: In response to these challenges, this study introduced an innovative deep-learning strategy designed for the efficient and precise identification of lung cancer-associated miRNAs. Through comprehensive benchmark tests, our method exhibited superior performance relative to existing technologies.

Conclusion: Further case studies have also confirmed the ability of our model to identify lung cancer-associated miRNAs that have undergone biological validation.

查看原文本刊更多论文

DeepLCRmiRNA：识别肺癌相关 miRNA 的混合神经网络方法

简介：肺癌是最常见的恶性肿瘤之一：肺癌是发病率最高的恶性肿瘤之一，微小 RNA（miRNA）在调节基因表达、影响癌细胞增殖、侵袭、转移、免疫逃逸和抗药性方面发挥着关键作用：方法：miRNA 在肺癌中的作用错综复杂，这凸显了它们作为早期检测生物标志物和治疗干预新靶点的重要意义。然而，鉴定与肺癌相关的 miRNAs 的传统方法因效率低下和复杂性而受到阻碍：为了应对这些挑战，本研究引入了一种创新的深度学习策略，旨在高效、精确地识别肺癌相关的 miRNA。通过全面的基准测试，我们的方法表现出优于现有技术的性能：进一步的案例研究也证实了我们的模型有能力识别经过生物学验证的肺癌相关 miRNA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current gene therapy 医学-遗传学

CiteScore

6.70

自引率

2.80%

发文量

期刊介绍： Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.